GlassScriptPhysician profile
Mika R Thomas
NPI 1932319209
$3,160.03
in general payments reported to CMS, 2019-2025
16 companies · $366 in 2025
The $366 reported for 2025 was more than what 82% of Reproductive Endocrinology providers received nationally (typical 2025 total: $140).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $913 · 2020: $349 · 2021: $493 · 2022: $313 · 2023: $340 · 2024: $385 · 2025: $366.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,091.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,091.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopersurgical, INC. | $864.68 | 2019-2025 | Stripper |
| Ferring Pharmaceuticals INC. | $710.42 | 2019-2025 | Menopur |
| Organon LLC | $495.40 | 2021-2025 | Follistim Aq, Pregnyl, Ganirelix Acetate |
| Abbvie INC. | $254.00 | 2019-2021 | |
| Emd Serono, INC. | $172.05 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $157.63 | 2019-2021 | |
| Covidien LP | $150.58 | 2019 | |
| Astellas Pharma US INC | $96.19 | 2024 | Veozah |
| Caldera Medical, INC | $89.59 | 2021 | |
| Meditrina | $64.47 | 2022-2025 | |
| Galen US INC | $26.98 | 2021 | |
| Minerva Surgical, INC | $23.09 | 2021 | |
| Exeltis, USA INC. | $17.78 | 2020 | |
| Vertical Pharmaceuticals, LLC | $13.34 | 2019 | |
| Duchesnay USA Incorporated | $12.78 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Therapeuticsmd, INC. | $11.05 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mika Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.